Drugs in R & D

, Volume 4, Issue 3, pp 198–203 | Cite as

Marimastat

BB 2516, TA 2516
Adis R&D Profile

References

  1. 1.
    Millar AW, Brown PD, Moore J. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. British Journal of Clinical Pharmacology 45: 21–26, Jan 1998CrossRefPubMedGoogle Scholar
  2. 2.
    Tierney GM, Griffin NR, Stuart RC, et al. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. European Journal of Cancer: Part A 35: 563–568, Apr 1999CrossRefGoogle Scholar
  3. 3.
    Rusmussen H, Rugg T, Brown P. A 371 patient meta-analysis of studies of marimastat in patients with advanced cancer. 33rd Annual Meeting of the American Society of Clinical Oncology: 429, 17 May 1997Google Scholar
  4. 4.
    Evans J, Bramhall S, Carmichael J, et al. A phase II study of marimastat (BB-2516) in advanced pancreatic cancer. Annals of Oncology 7 (Suppl. 5): 51, 1996Google Scholar
  5. 5.
    Boasberg P, Harbaugh, Eisenberger M. Marimastat in patients with hormone refractory prostate cancer: a dose-finding study. 33rd Annual Meeting of the American Society of Clinical Oncology: 316, 17 May 1997Google Scholar
  6. 6.
    Bodurtha A, Eisenhauer E, Steward W. Phase I-II study of marimastat (BB2516) in patients with metastatic melanoma. 33rd Annual Meeting of the American Society of Clinical Oncology: 493, 17 May 1997Google Scholar
  7. 7.
    Wojtowicz-Praga S, Torri J, Johnson M, et al. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. Journal of Clinical Oncology 16: 2150–2156, Jun 1998PubMedGoogle Scholar
  8. 8.
    Primrose JN, Bleiberg H, Daniel F, et al. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. British Journal of Cancer 79: 509–514, No. 3-4, Feb 1999CrossRefPubMedGoogle Scholar
  9. 9.
    King J, Clingan P, Morris DL. Placebo control double-blind randomised clinical trial of the matrix metalloproteinase inhib-itor marimastat in patients with inoperable colorectal cancer liver metastases: significant survival advantage in patients with musculoskeletal symptoms. 38th Annual Meeting of the American Society of Clinical Oncology 21: 135, Part 1, 18 May 2002Google Scholar
  10. 10.
    British Biotech plc. British Biotech plc announces results of marimastat study 145 in gastric cancer. Media Release: [3 pages], 24 Aug 1999Google Scholar
  11. 11.
    Fielding J, Scholefield J, Stuart R, et al. A randomized doubleblind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma. 36th Annual Meeting of the American Society of Clinical Oncology 19: 240, 20 May 2000Google Scholar
  12. 12.
    British Biotech plc. British Biotech plc results of marimastat study 186 in patients with advanced ovarian cancer. Media Release [2 pages], 26 Sep 2000. Available from: URL: http://www.britbio.co.uk Google Scholar
  13. 13.
    Rosemurgy A, Harris J, Langleben A, et al. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. American Journal of Clinical Oncology 22: 247–252, Jun 1999CrossRefPubMedGoogle Scholar
  14. 14.
    British Biotech. British Biotech plc —results of marimastat study 128 —pancreatic cancer monotherapy trial. Media Release: [3 pages], 15 Feb 1999Google Scholar
  15. 15.
    Evans JD, Stark A, Johnson CD, et al. A phase II trial of marimastat in advanced pancreatic cancer. British Journal of Cancer 85: 1865–1870, No. 12, 14 Dec 2001CrossRefPubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Personalised recommendations